

# Sumit Kumar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8053948/publications.pdf>

Version: 2024-02-01

15  
papers

645  
citations

840776

11  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical stability of nanosuspensions: Investigation of the role of stabilizers on Ostwald ripening. International Journal of Pharmaceutics, 2011, 406, 145-152.	5.2	220
2	Sugars as bulking agents to prevent nano-crystal aggregation during spray or freeze-drying. International Journal of Pharmaceutics, 2014, 471, 303-311.	5.2	65
3	Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole. Journal of Controlled Release, 2014, 192, 95-102.	9.9	61
4	Quality by Design approach to spray drying processing of crystalline nanosuspensions. International Journal of Pharmaceutics, 2014, 464, 234-242.	5.2	55
5	Wet milling induced physical and chemical instabilities of naproxen nano-crystalline suspensions. International Journal of Pharmaceutics, 2014, 466, 223-232.	5.2	48
6	Formulation parameters of crystalline nanosuspensions on spray drying processing: A DoE approach. International Journal of Pharmaceutics, 2014, 464, 34-45.	5.2	45
7	In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole. Journal of Pharmaceutical Sciences, 2015, 104, 3018-3028.	3.3	29
8	Optimization and dissolution performance of spray-dried naproxen nano-crystals. International Journal of Pharmaceutics, 2015, 486, 159-166.	5.2	26
9	Formulation and performance of Irbesartan nanocrystalline suspension and granulated or bead-layered dried powders – Part I. International Journal of Pharmaceutics, 2019, 568, 118189.	5.2	25
10	Formulation design and evaluation of amorphous ABT-102 nanoparticles. International Journal of Pharmaceutics, 2016, 498, 153-169.	5.2	20
11	Formulation and Performance of Danazol Nano-crystalline Suspensions and Spray Dried Powders. Pharmaceutical Research, 2015, 32, 1694-1703.	3.5	19
12	Downstream processing of irbesartan nanocrystalline suspension and mini-tablet development – Part II. International Journal of Pharmaceutics, 2019, 568, 118509.	5.2	10
13	A new combination approach of CI jet and QESD to formulate pH-susceptible amorphous solid dispersions. International Journal of Pharmaceutics, 2014, 466, 368-374.	5.2	8
14	Role of wetting agents and disintegrants in development of danazol nanocrystalline tablets. International Journal of Pharmaceutics, 2020, 577, 119026.	5.2	8
15	A Novel Use of Nanocrystalline Suspensions to Develop Sub-Microgram Dose Micro-Tablets. Journal of Pharmaceutical Sciences, 2021, 110, 3276-3288.	3.3	6